These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32000822)

  • 1. Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults.
    Kemppinen A; Howell C; Allgar V; Dodd M; Gregson J; Knowles C; McLaughlin J; Pandya P; Whorwell P; Markaryan E; Yiannakou Y
    Trials; 2020 Jan; 21(1):122. PubMed ID: 32000822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D).
    Howell CA; Kemppinen A; Allgar V; Dodd M; Knowles CH; McLaughlin J; Pandya P; Whorwell P; Markaryan E; Yiannakou Y
    Gut; 2022 Dec; 71(12):2430-2438. PubMed ID: 35760493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.
    Leighton MP; Lam C; Mehta S; Spiller RC
    Trials; 2013 Jan; 14():10. PubMed ID: 23302220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial.
    Gunn D; Fried R; Lalani R; Farrin A; Holloway I; Morris T; Olivier C; Kearns R; Corsetti M; Scott M; Farmer A; Emmanuel A; Whorwell P; Yiannakou Y; Sanders D; Mclaughlin J; Kapur K; Eugenicos M; Akbar A; Trudgill N; Houghton L; Dinning PG; Ford AC; Aziz Q; Spiller R
    Trials; 2019 Aug; 20(1):517. PubMed ID: 31429811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial.
    Anderle K; Wolzt M; Moser G; Keip B; Peter J; Meisslitzer C; Gouya G; Freissmuth M; Tschegg C
    World J Gastroenterol; 2022 Dec; 28(46):6573-6588. PubMed ID: 36569277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.
    Aroniadis OC; Brandt LJ; Oneto C; Feuerstadt P; Sherman A; Wolkoff AW; Kassam Z; Sadovsky RG; Elliott RJ; Budree S; Kim M; Keller MJ
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):675-685. PubMed ID: 31326345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.
    Lacy BE; Chang L; Rao SSC; Heimanson Z; Sayuk GS
    Clin Ther; 2023 Mar; 45(3):198-209. PubMed ID: 36922331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
    Bai T; Zeng H; Long Y; Li X; Sun X; Lan Y; Gao L; Zhang L; Feng Z; Hou X
    Trials; 2020 Jun; 21(1):597. PubMed ID: 32605578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS.
    Tack J; Schumacher K; Tonini G; Scartoni S; Capriati A; Maggi CA;
    Gut; 2017 Aug; 66(8):1403-1413. PubMed ID: 27196574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
    Holvoet T; Joossens M; Vázquez-Castellanos JF; Christiaens E; Heyerick L; Boelens J; Verhasselt B; van Vlierberghe H; De Vos M; Raes J; De Looze D
    Gastroenterology; 2021 Jan; 160(1):145-157.e8. PubMed ID: 32681922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.
    Johnsen PH; Hilpüsch F; Cavanagh JP; Leikanger IS; Kolstad C; Valle PC; Goll R
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):17-24. PubMed ID: 29100842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Otilonium bromide in irritable bowel syndrome: a dose-ranging randomized double-blind placebo-controlled trial.
    Chmielewska-Wilkoń D; Reggiardo G; Egan CG
    World J Gastroenterol; 2014 Sep; 20(34):12283-91. PubMed ID: 25232263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live
    Srivastava S; Basak U; Naghibi M; Vijayakumar V; Parihar R; Patel J; Jadon PS; Pandit A; Dargad RR; Khanna S; Kumar S; Day R
    Gut Microbes; 2024; 16(1):2338322. PubMed ID: 38630015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome.
    Chen M; Tang TC; Wang Y; Shui J; Xiao XH; Lan X; Yu P; Zhang C; Wang SH; Yao J; Zheng H; Huang DQ
    Aliment Pharmacol Ther; 2018 Jul; 48(2):160-168. PubMed ID: 29856472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
    Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
    Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care.
    Alderson SL; Wright-Hughes A; Ford AC; Farrin A; Hartley S; Fernandez C; Taylor C; Ow PL; Teasdale E; Howdon D; Guthrie E; Foy R; Ridd MJ; Bishop FL; Muir D; Chaddock M; Herbert A; Cooper D; Gibbins R; Newman S; Cook H; Longo R; Everitt H
    Trials; 2022 Jul; 23(1):552. PubMed ID: 35804433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT.
    Everitt H; Landau S; Little P; Bishop FL; O'Reilly G; Sibelli A; Holland R; Hughes S; Windgassen S; McCrone P; Goldsmith K; Coleman N; Logan R; Chalder T; Moss-Morris R
    Health Technol Assess; 2019 Apr; 23(17):1-154. PubMed ID: 31042143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of acupuncture for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized clinical trial.
    Qi LY; Yang JW; Yan SY; She YF; Hu H; Li Y; Chi LL; Wu BQ; Tu JF; Wang LQ; Liu CZ
    Trials; 2022 Aug; 23(1):711. PubMed ID: 36028847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D).
    Lam C; Tan W; Leighton M; Hastings M; Lingaya M; Falcone Y; Zhou X; Xu L; Whorwell P; Walls AF; Zaitoun A; Montgomery A; Spiller R
    Gut; 2016 Jan; 65(1):91-9. PubMed ID: 25765462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.